J Nemunaitis

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. doi request reprint Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy
    Walter J Urba
    Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Urol 180:2011-7; discussion 2017-8. 2008
  2. ncbi request reprint Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors
    Lynne R Pauer
    Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Cancer Invest 22:886-96. 2004
  3. ncbi request reprint Vaccines in cancer: GVAX, a GM-CSF gene vaccine
    John Nemunaitis
    Expert Rev Vaccines 4:259-74. 2005
  4. ncbi request reprint Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    John Nemunaitis
    US Oncology, Dallas, Texas 75246, USA
    Cancer Gene Ther 10:341-52. 2003
  5. ncbi request reprint Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region
    Jerry Edelman
    US Oncology Inc, Collins Building, 3535 Worth Street, Dallas, TX 75246, USA
    Curr Opin Mol Ther 5:611-7. 2003
  6. ncbi request reprint Selectively replicating viral vectors
    John Nemunaitis
    US Oncology, Inc, Collins Building, 5th Floor, Dallas, Texas 75246, USA
    Cancer Gene Ther 9:987-1000. 2002
  7. ncbi request reprint Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer
    John J Nemunaitis
    US Oncology, Baylor University Medical Center, Dallas, Texas, USA
    Cancer J 9:58-66. 2003
  8. ncbi request reprint Enhanced oncolytic potency of replicative adenovirus expressing p53
    John Nemunaitis
    US Oncology, Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA
    Drug Resist Updat 6:5-7. 2003
  9. ncbi request reprint Selective replicating viral vectors : potential for use in cancer gene therapy
    John Nemunaitis
    US Oncology Inc, Dallas, Texas, USA
    BioDrugs 17:251-62. 2003
  10. ncbi request reprint GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer
    John Nemunaitis
    US Oncology, Dallas, TX, USA
    J Control Release 91:225-31. 2003

Detail Information

Publications74

  1. doi request reprint Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy
    Walter J Urba
    Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Urol 180:2011-7; discussion 2017-8. 2008
    ..This phase I-II study evaluated the safety, clinical activity and immunogenicity of an immunotherapy developed from human prostate cancer cell lines (PC-3 and LNCaP) modified to secrete granulocyte-macrophage colony-stimulating factor...
  2. ncbi request reprint Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors
    Lynne R Pauer
    Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Cancer Invest 22:886-96. 2004
    ..To determine maximum tolerated dose of CI-994, a novel oral histone deacetylase inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors...
  3. ncbi request reprint Vaccines in cancer: GVAX, a GM-CSF gene vaccine
    John Nemunaitis
    Expert Rev Vaccines 4:259-74. 2005
    ..The rationale of GVAX development and a summary of clinical results are reviewed...
  4. ncbi request reprint Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    John Nemunaitis
    US Oncology, Dallas, Texas 75246, USA
    Cancer Gene Ther 10:341-52. 2003
    ..Further investigation of ONYX-015, possibly with agents that may modulate replication activity, or duration of virus survival, is indicated...
  5. ncbi request reprint Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region
    Jerry Edelman
    US Oncology Inc, Collins Building, 3535 Worth Street, Dallas, TX 75246, USA
    Curr Opin Mol Ther 5:611-7. 2003
    ..This review will summarize phase I and II trial results. Conclusions drawn from these studies justify the currently ongoing phase III investigation...
  6. ncbi request reprint Selectively replicating viral vectors
    John Nemunaitis
    US Oncology, Inc, Collins Building, 5th Floor, Dallas, Texas 75246, USA
    Cancer Gene Ther 9:987-1000. 2002
  7. ncbi request reprint Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer
    John J Nemunaitis
    US Oncology, Baylor University Medical Center, Dallas, Texas, USA
    Cancer J 9:58-66. 2003
    ..The purpose of this study was to determine the maximum tolerated dose, pharmacokinetic profile, and evidence of antitumor activity of CI-994 used in combination with gemcitabine...
  8. ncbi request reprint Enhanced oncolytic potency of replicative adenovirus expressing p53
    John Nemunaitis
    US Oncology, Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA
    Drug Resist Updat 6:5-7. 2003
  9. ncbi request reprint Selective replicating viral vectors : potential for use in cancer gene therapy
    John Nemunaitis
    US Oncology Inc, Dallas, Texas, USA
    BioDrugs 17:251-62. 2003
    ..Modifications may one day enable more aggressive use of these new and exciting therapeutics as systemic gene delivery vehicles...
  10. ncbi request reprint GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer
    John Nemunaitis
    US Oncology, Dallas, TX, USA
    J Control Release 91:225-31. 2003
    ..These results supported further clinical investigation with GVAX in non-small cell lung cancer...
  11. ncbi request reprint Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients
    John Nemunaitis
    US Oncology, Mary Crowley Medical Research Center, and Baylor University Medical Center, 3535 Wirth St, Dallas, Texas 75246, USA
    Cancer Gene Ther 10:737-44. 2003
    ..e. able to convert 5-FC to 5-FU) at doses at or below 3 x 10(7) CFU/m(2)...
  12. ncbi request reprint Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer
    John Nemunaitis
    US Oncology, Dallas, TX, USA
    J Natl Cancer Inst 96:326-31. 2004
    ..028), suggesting a vaccine dose-related survival advantage...
  13. ncbi request reprint Head and neck cancer: gene therapy approaches. Part II: genes delivered
    John Nemunaitis
    3535 Worth Street, Collins Building, 5th Floor, Dallas, Texas 75246, USA
    Expert Opin Biol Ther 2:311-24. 2002
    ..Preliminary Phase I and II results suggest evidence of efficacy and justify accrual Phase III trials, which are currently ongoing...
  14. ncbi request reprint Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors
    John Nemunaitis
    3535 Worth Street, Collins Building, 5th Floor, Dallas, Texas 75246, USA
    Expert Opin Biol Ther 2:177-85. 2002
    ....
  15. ncbi request reprint Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients
    John Nemunaitis
    US Oncology, Dallas, Texas, USA
    Cancer Invest 22:360-7. 2004
    ..To determine maximum tolerated dose (MTD) and evidence of antitumor activity of topotecan in combination with gemcitabine in refractory cancer patients...
  16. ncbi request reprint Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors
    J Nemunaitis
    US Oncology, Dallas, Texas 75246, USA
    J Clin Oncol 18:3423-34. 2000
    ..To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors...
  17. ncbi request reprint Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial
    J Nemunaitis
    US Oncology, Dallas, Texas 75246, USA
    Cancer Res 60:6359-66. 2000
    ..This agent demonstrates the promise of replication-selective viruses as a novel therapeutic platform against cancer...
  18. ncbi request reprint Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
    J Nemunaitis
    US Oncology, Dallas, TX 75246, USA
    J Clin Oncol 19:289-98. 2001
    ..To determine the safety, humoral immune response replication, and activity of multiple intratumoral injections of ONYX-015 (replication selective adenovirus) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)...
  19. ncbi request reprint Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma
    J Nemunaitis
    Baylor University Medical Center, Dallas, Texas, USA
    Cancer Invest 19:239-47. 2001
    ..Survival of melanoma patients with an IL-10 level above 10.0 pg/ml was 365 days compared to 557 days in patients with IL-10 levels less than 10.0 pg/ml (p = 0.0259, Wilcoxon). Elevated IL-10 levels were correlated with poor survival...
  20. ncbi request reprint Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
    J Nemunaitis
    US Oncology, Dallas, TX 75246, USA
    Gene Ther 8:746-59. 2001
    ..The intravenous administration of genetically altered adenovirus is a feasible approach...
  21. ncbi request reprint Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
    J Nemunaitis
    US Oncology, Baylor University Medical Center, Dallas, TX, USA
    J Clin Oncol 18:609-22. 2000
    ..To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non-small-cell lung cancer (NSCLC)...
  22. ncbi request reprint Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma
    J Nemunaitis
    PRN Research, Inc, Dallas, TX 75246, USA
    Hum Gene Ther 10:1289-98. 1999
    ..0462, Wilcoxon; p = 0.0273, log rank). We conclude that intratumor injection of IFN-gamma is safe and well tolerated. Evidence of antitumor activity is suggested in patients with advanced malignancy that received multiple injections...
  23. doi request reprint Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
    J Nemunaitis
    Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
    Cancer Gene Ther 16:620-4. 2009
    ..A larger clinical trial is warranted to further explore this observation...
  24. doi request reprint Clinical development directions in oncolytic viral therapy
    R M Eager
    Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
    Cancer Gene Ther 18:305-17. 2011
    ..The major challenge for researchers is to maximize the efficacy of these viral therapeutics, and to establish stable systemic delivery mechanisms...
  25. doi request reprint MicroRNA profile analysis of human prostate cancers
    A W Tong
    Gradalis, Inc, Dallas, TX, USA
    Cancer Gene Ther 16:206-16. 2009
    ..Growth inhibition through the reconstitution of miRNAs is potentially applicable for experimental therapy of prostate cancer, pending molecular validation of targeted genes...
  26. doi request reprint Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
    J Nemunaitis
    Clinical Research, Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
    Gene Ther 20:875-9. 2013
    ....
  27. ncbi request reprint A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
    J Nemunaitis
    Mary Crowley Medical Research Center, Dallas, TX, USA
    Cancer Gene Ther 14:885-93. 2007
    ..Area under the curve determinations indicate a marked higher level of TNF-alpha induction and accelerated clearance at cycle 2 in the absence of enbrel. Further assessment is recommended...
  28. ncbi request reprint Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer
    S Singh
    US Oncology, Dallas, Texas 75246, USA
    Mol Ther 4:157-60. 2001
    ..We identified no tumor responses of the injected lesions. Of 13 patients with advanced melanoma, 6 survived over one year. Thus, injection of retroviral delivered HSV-TK in patients with refractory cancer was well-tolerated...
  29. doi request reprint Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference
    D D Rao
    Gradalis, Inc, Dallas, TX, USA
    Cancer Gene Ther 17:780-91. 2010
    ..The bifunctional shRNA is a highly effective and advantageous approach mediating RNAi at concentrations significantly lower than conventional shRNA or siRNA. These results support further evaluations...
  30. ncbi request reprint Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development
    D D Rao
    Gradalis Inc, Dallas, TX, USA
    Cancer Gene Ther 16:807-9. 2009
    ..This review considers comparisons of the off-target effects of siRNA to shRNA and their potential impact on the efficacy and toxicity of RNAi based therapeutics...
  31. doi request reprint Transcription factors: their potential as targets for an individualized therapeutic approach to cancer
    C Mees
    Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
    Cancer Gene Ther 16:103-12. 2009
    ....
  32. doi request reprint Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer
    R M Eager
    Mary Crowley Cancer Research Centers, Dallas, Texas, USA
    Clin Oncol (R Coll Radiol) 21:464-72. 2009
    ..The aim of this study was to determine the efficacy and safety of talabostat in NSCLC patients...
  33. ncbi request reprint A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
    C C Cunningham
    U S Oncology, Dallas, Texas, USA
    Cancer 92:1265-71. 2001
    ..Here, the authors report an initial clinical study of the safety and tolerability of an intravenous infusion of ISIS 2503 in patients with advanced cancer...
  34. doi request reprint A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers
    J Nemunaitis
    Mary Crowley Cancer Research Centers, Clinical Research, Dallas, TX 75201, USA
    Clin Oncol (R Coll Radiol) 25:336-42. 2013
    ..This phase I dose-escalation study was designed to evaluate the combination of the mammalian target of rapamycin inhibitor ridaforolimus with the vascular endothelial growth factor inhibitor bevacizumab...
  35. doi request reprint Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?
    A W Tong
    Mary Crowley Cancer Research Centers, Dallas, TX, USA
    Cancer Gene Ther 15:341-55. 2008
    ....
  36. ncbi request reprint Proof concept for clinical justification of network mapping for personalized cancer therapeutics
    J Nemunaitis
    Mary Crowley Medical Research Center, Dallas, TX, USA
    Cancer Gene Ther 14:686-95. 2007
    ..Further animal safety testing followed by clinical study is recommended...
  37. ncbi request reprint A review of vaccine clinical trials for non-small cell lung cancer
    J Nemunaitis
    Mary Crowley Medical Research Center, 60th Floor, 1717 Main St, Dallas, Texas 75201, USA
    Expert Opin Biol Ther 7:89-102. 2007
    ..Specific vaccines fulfilling justification for Phase III evaluation based on these results include LBLP25, TGF-beta2 antisense gene vaccine and GVAX...
  38. ncbi request reprint Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer
    J Nemunaitis
    Mary Crowley Medical Research Center, Baylor University Medical Center, Texas Oncology PA, Dallas, TX 75201, USA
    Cancer Gene Ther 13:555-62. 2006
    ..However, the frequency of vaccine site reactions, tumor response, time to disease progression, and survival were all less favorable in the current study...
  39. ncbi request reprint Herpes simplex virus 1 (HSV-1) for cancer treatment
    Y Shen
    Mary Crowley Medical Research Center, Dallas, TX 75201, USA
    Cancer Gene Ther 13:975-92. 2006
    ..This review briefly summarizes the biology of HSV-1, examines various strategies that have been used to genetically modify the virus, and discusses preclinical as well as clinical results of the HSV-1-derived vectors in cancer treatment...
  40. doi request reprint Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine
    C M Jay
    Gradalis, Dallas, TX, USA
    Cancer Gene Ther 20:683-9. 2013
    ..In conclusion, a single intravenous infusion of OFHIRNA-PDX1 in conjunction with premedication in pigs was well tolerated and demonstrated significant PDX1 knockdown. ..
  41. ncbi request reprint Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
    R H Collins
    Texas Oncology, PA, Dallas, USA
    J Clin Oncol 15:433-44. 1997
    ..We performed a retrospective study to characterize better this new treatment modality...
  42. ncbi request reprint Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer
    Ralph G Zinner
    M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:3006-14. 2007
    ..Plasma biomarkers HER2, vascular endothelial growth factor, interleukin-8, and matrix metalloproteinase-9 were evaluated using immunologic techniques...
  43. ncbi request reprint Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients
    Alex W Tong
    Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Mol Ther 11:160-72. 2005
    ..Intratumoral delivery of INGN 241 induced apoptosis in a large volume of tumor and elicited tumor-regulatory and immune-activating events that are consistent with the preclinical features of MDA-7/IL-24...
  44. ncbi request reprint Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study
    C Casey Cunningham
    Mary Crowley Medical Research Center, Dallas, TX 75246, USA
    Mol Ther 11:149-59. 2005
    ..Thus intratumoral administration of INGN 241 is well tolerated, induces apoptosis in a large percentage of tumor cells, and demonstrates evidence of clinically significant activity...
  45. pmc Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation
    Dan Laheru
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Public Health, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:1455-63. 2008
    ....
  46. ncbi request reprint mda-7/IL-24: exploiting cancer's Achilles' heel
    Irina V Lebedeva
    Department of Pathology, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA
    Mol Ther 11:4-18. 2005
    ....
  47. ncbi request reprint Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer
    John Nemunaitis
    Mary Crowley Medical Research Center Texas Oncology PA, Dallas, Texas, USA
    Clin Cancer Res 11:3846-53. 2005
    ..To determine the tolerability and pharmacokinetics of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, administered over 14 consecutive days of a 21-day cycle...
  48. ncbi request reprint A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities
    Arno J Mundt
    University of Chicago Medical Center, Chicago, Illinois, USA
    Clin Cancer Res 10:5747-53. 2004
    ..The objective of this study was to assess the tolerance of combining TNFerade and radiation therapy in patients with soft tissue sarcomas of the extremity...
  49. ncbi request reprint Oncolytic viral therapies
    Eugene Lin
    Mary Crowley Medical Research Center, Dallas, Texas, USA
    Cancer Gene Ther 11:643-64. 2004
    ..Safety has been confirmed and despite variable efficacy results several dramatic responses have been observed with some oncolytic viruses. This review summarizes results of clinical trials with oncolytic viruses in cancer...
  50. ncbi request reprint TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors
    Neil Senzer
    US Oncology, Dallas, TX, USA
    J Clin Oncol 22:592-601. 2004
    ..The goals of this study were to determine the safety and toxicity of TNFerade in combination with radiation therapy...
  51. ncbi request reprint Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer
    Jackie Nemunaitis
    Baylor University Medical Center, Dallas, Texas, USA
    Clin Lung Cancer 5:148-57. 2003
    ..Patients with metastatic NSCLC who had previously failed chemotherapy demonstrated response to GVAX (3 of 33 complete responses) and dose-related improvement in survival (471 days vs. 174 days)...
  52. ncbi request reprint Live viruses in cancer treatment
    John Nemunaitis
    Mary Crowley Medical Clinic, Research Center, Dallas, Texas, USA
    Oncology (Williston Park) 16:1483-92; discussion 1495-7. 2002
    ..This article explores the principles of viral therapy for cancer and the past several decades of investigations with viruses such as Egypt 101, mumps, Newcastle disease, influenza, vaccinia, herpes simplex, and adenovirus serotype 5...
  53. ncbi request reprint Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors
    John Nemunaitis
    US Oncology, Mary Crowley Medical Research Center, Baylor University Medical Center, 3535 Worth Street, Collins Building, 5th Floor, Dallas, TX 75246, USA
    Drug Resist Updat 5:34-46. 2002
    ..In this review, we survey a sampling of current therapeutic approaches that depend upon adenoviral delivery vehicles and outline the advantages and disadvantages of this vector system...
  54. ncbi request reprint Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer
    Robert S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08901, USA
    J Clin Oncol 20:1874-9. 2002
    ....
  55. ncbi request reprint Immune-modulating vaccines in non-small cell lung cancer
    John Nemunaitis
    Mary Crowley Medical Research Center, Dallas, Texas, USA
    J Thorac Oncol 1:756-61. 2006
    ..Further studies are needed to demonstrate whether these novel therapies can potentially complement or replace current therapeutic approaches...
  56. ncbi request reprint Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer
    John Nemunaitis
    Mary Crowley Medical Research Center, Texas Oncology PA, Dallas, TX 75201, USA
    Mol Ther 13:1185-91. 2006
    ..Results suggest a high level of safety but evidence of L523S-directed immune activation was limited, suggesting a need for modification of dose, schedule, and site of vaccination (i.e., intradermal) with further clinical testing...
  57. ncbi request reprint Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients
    John Nemunaitis
    Mary Crowley Medical Research Center, USA
    J Oncol Manag 14:77-90. 2005
    ..In conclusion, we recommend further investigation of oral topotecan (1.5 mg/m2/d(-1)) on days 1 to 5 of each week for 2 weeks in combination with capecitabine (180 mg/m2 twice daily) on days 1 to 14 within a 21-day cycle...
  58. ncbi request reprint Fighting cancer with vaccinia virus: teaching new tricks to an old dog
    Yuqiao Shen
    Mary Crowley Medical Research Center, 1717 Main Street, 60th Floor, Dallas, TX 75201, USA
    Mol Ther 11:180-95. 2005
    ....
  59. ncbi request reprint TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up
    James M McLoughlin
    Department of Surgery, Sammons Cancer Center of Baylor University Medical Center, Worth Street 420, Dallas, Texas 75246, USA
    Ann Surg Oncol 12:825-30. 2005
    ..Many of these studies demonstrated dose-limiting systemic side effects from high concentrations of TNF-alpha. The recent focus has been on developing a local delivery system for TNF-alpha to minimize the systemic response...
  60. ncbi request reprint GM-CSF gene-transduced tumor vaccines
    Robert Eager
    Mary Crowley Medical Research Center Texas Oncology PA, Dallas, TX 75201, USA
    Mol Ther 12:18-27. 2005
    ..Results of preclinical studies justify clinical investigation. A summary of clinical results is presented...
  61. ncbi request reprint Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
    John Nemunaitis
    Mary Crowley Medical Research Center Texas Oncology Professional Association, Dallas, TX, USA
    J Clin Oncol 24:4721-30. 2006
    ..Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition...
  62. ncbi request reprint Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy
    John Nemunaitis
    Mary Crowley Medical Research Center, Sammons Cancer Center, Baylor University Hospital, Dallas, Texas, USA
    Cancer Invest 24:553-61. 2006
    ....
  63. ncbi request reprint Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA
    Yu An Zhang
    The Mary Crowley Medical Research Center, Dallas, Texas
    Cancer Res 66:9736-43. 2006
    ..These findings indicate that Internavec can generate a two-pronged attack on tumor cells through oncogene knockdown and viral oncolysis, resulting in a significantly enhanced antitumor outcome...
  64. ncbi request reprint Phase 2 trial of Allovectin-7 in advanced metastatic melanoma
    Rene Gonzalez
    University of Colorado Cancer Center, Aurora, CO 80010 5010, USA
    Melanoma Res 16:521-6. 2006
    ..8 months median duration of response. Allovectin-7 was shown to be safe and exhibit biological activity at this dose. Its safety profile may enable Allovectin-7 to be used at higher doses, which may provide greater clinical activity...
  65. ncbi request reprint Bacteria in the treatment of cancer
    John Lin
    Mary Crowley Medical Research Center, Texas Oncology PA, 3535 Worth Street, Dallas, TX 75246, USA
    Curr Opin Mol Ther 6:629-39. 2004
    ..Preclinical and early clinical results presented indicate a high safety profile and demonstrate clear anticancer activity, thereby justifying further investigation of bacteria as a therapeutic approach in the treatment of cancer...
  66. ncbi request reprint Small interfering RNA for experimental cancer therapy
    Alex W Tong
    Baylor University Medical Center, Baylor Sammons Cancer Center, Mary Crowley Medical Research Center, Research Laboratory, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Curr Opin Mol Ther 7:114-24. 2005
    ....
  67. pmc Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma
    Paul B Fisher
    Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA
    Toxicol Appl Pharmacol 224:300-7. 2007
    ..These results provide an impetus for further clinical studies and document a central paradigm of cancer therapy, namely translation of basic science from the "bench to the bedside."..
  68. ncbi request reprint Individualised cancer therapeutics: dream or reality? Therapeutics construction
    Yuqiao Shen
    Mary Crowley Medical Research Center, Dallas, TX 75201, USA
    Expert Opin Biol Ther 5:1427-41. 2005
    ..The authors will discuss gene-modified conditionally replicating viruses as candidate vehicles for the delivery of RNAi...
  69. ncbi request reprint Individualised cancer therapeutics: dream or reality?
    Neil Senzer
    Mary Crowley Medical Research Center, Collins Building, Suite 302, Dallas, TX 75246, USA
    Expert Opin Ther Targets 9:1189-201. 2005
    ..Such evidence supports the strategy of individualised selection of a therapeutic complex from a menu of targeting options that best complements the specific oncomolecular profile of the 'tumour-host' system...
  70. ncbi request reprint Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors
    John Nemunaitis
    Mary Crowley Medical Research Center, Dallas, TX 75201, USA
    Cancer Invest 23:671-6. 2005
    ....
  71. ncbi request reprint Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies
    John S Vorhies
    Mary Crowley Medical Research Center, 1717 Main St, Suite 6000, Dallas, TX 75201, USA
    Expert Rev Anticancer Ther 7:373-82. 2007
    ..Here, we review the most promising current nonviral gene delivery vehicles with a focus on their potential use in cancer shRNA therapeutics...
  72. ncbi request reprint Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    Eric J Small
    University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California 94115, USA
    Clin Cancer Res 13:3883-91. 2007
    ..The immunotherapy, based on the GVAX platform, is a combination of two prostate carcinoma cell lines modified with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene...
  73. ncbi request reprint miRNA profiling for diagnosis and prognosis of human cancer
    Chris Jay
    Murex Pharmaceuticals, Dallas, Texas, USA
    DNA Cell Biol 26:293-300. 2007
    ..The evaluation of miRNAs expression may also be of prognostic value, as best exemplified by the correlation of let-7 and mir-155 levels with disease survival in nonsmall cell lung cancer...
  74. ncbi request reprint p53 therapy in a patient with Li-Fraumeni syndrome
    Neil Senzer
    Mary Crowley Medical Research Center, Baylor University Medical Center, 60th Floor, 1717 Main Street, Dallas, TX 75201, USA
    Mol Cancer Ther 6:1478-82. 2007
    ..Relationships between these clinical, radiographic, and molecular markers may prove useful in guiding future application of p53 tumor suppressor therapy...